In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants

被引：36
|
作者：
Brunelle, M. N.
Lucifora, J.
Neyts, J.
Villet, S.
Holy, A.
Trepo, C.
Zoulim, F.
机构：
[1] INSERM, U871, F-69003 Lyon, France
[2] Univ Lyon 1, F-69008 Lyon, France
[3] Fac Med Laennec, IFR62, F-69008 Lyon, France
[4] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[5] Acad Sci Czech Republ, Inst Organ Chem & Biochem, Prague, Czech Republic
[6] Hop Hotel Dieu, Hospices Civils, F-69002 Lyon, France
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 06期
关键词：
D O I：
10.1128/AAC.01440-06
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.
引用
收藏
页码：2240 / 2243
页数：4
相关论文
共 34 条
1234